Senator Grassley seeks info on Novartis's Zolgensma data issues

U.S. Senate Finance Committee Chairman Chuck Grassley has sought more information from Swiss drugmaker Novartis AG on the reasons for "intentional withholding" of data related to its $2 million gene therapy, Zolgensma, by Aug. 23.